Recent Finacing
Recent Raise
NXI Therapeutics, a University of Basel spin-off, develops coronin 1–targeting immunotherapies to induce transplant tolerance and treat T cell–mediated autoimmune diseases, currently in preclinical development.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
